Seizure and Prison for Owner of Immuno Biotec

Recommendation
12/13 November 2025
How to implement EU-GMP Chapter 8
After a four-year investigation by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) (and with the support of the London Regional Asset Recovery Team, RART), the owner of Guernsey-based Immuno Biotech is now facing a £1.4 million seizure, including private property.
He has already served a 15-month prison sentence based on four counts of manufacturing, selling and supplying an unlicensed drug (plus one for money laundering).
Immuno Biotech was a distributor of a human blood product called Globulin component Macrophage Activating Factor (GcMAF). GcMAF was advertised and sold over the Internet as a so-called "miracle cure" for various diseases and conditions. Following an investigation, the MHRA confiscated more than 10,000 vials of the product and issued a warning to the public.
Source: GOV.UK provided by the Government Digital Service.
Related GMP News
22.10.2025Content Review of the Audit Trail Review
15.10.2025Executing the Audit Trail Review
08.10.2025Risk-based Determination of the Scope and Frequency of Audit Trail Reviews
01.10.2025Decentralised Manufacturing: New UK Framework in Operation
24.09.2025Responsibilities for the Audit Trail (Review)
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025


